Agentic AI-EnableD CardioVascular CAre TransfOrmation (ADVOCATE) Innovative Solutions Opening (ISO) ARPA-H-SOL-26-142

The Advanced Research Projects Agency for Health (ARPA-H) Agentic AI-Enabled Cardiovascular Care Transformation (ADVOCATE) program will enable the development of an Agentic system that delivers autonomous and semi-autonomous clinical care directly to patients with cardiovascular disease (CVD). Interested parties are invited to review the attached ADVOCATE Innovative Solutions Opening (ISO) ARPA-H -SOL-26-142. For detailed information regarding the ADVOCATE Proposers' Day, review Special Notice (SN) ARPA-H-SN-26-139.

February 5, 2026 ADVOCATE ISO, ARPA-H-SOL-26-142, Amendment 01: The purpose of ARPA-H-SOL-26-142, Amendment 01 is as follows: Make a correction to Table 7 Performer Collaboration Expectations under Section 1.2.5 Performer Collaboration Expectations (See highlighted text). Revise the last paragraph under Section 5.1 Proposing Teams (See highlighted text) to read: Proposers interested in submitting a proposal for TA3 cannot submit a proposal for TA1 and TA2 in any capacity (e.g. prime, subperformer, or multi-party team). TA3 proposers can only submit one proposal for the TA3 work outlined in this solicitation. Update the first sentence of Section 6.2 Organization Conflicts of Interest (OCI) (See highlighted text) to read: The proposer, through submission of a proposal, is required to identify and disclose all facts relevant to any potential OCI involving the proposer, its organization, and/or any proposed team member (i.e. proposed sub-performer, consultant). See attached ADVOCATE ISO, ARPA-H-SOL-26-142, Amendment 01. ___________________ January 13, 2026 The Advanced Research Projects Agency for Health (ARPA-H) Agentic AI-Enabled Cardiovascular Care Transformation (ADVOCATE) program will enable the development of an Agentic system that delivers autonomous and semi-autonomous clinical care directly to patients with cardiovascular disease (CVD). Interested parties are invited to review the attached ADVOCATE Innovative Solutions Opening (ISO) ARPA-H -SOL-26-142. For detailed information regarding the ADVOCATE Proposers' Day, review Special Notice (SN) ARPA-H-SN-26-139.

February 23, 2026 ADVOCATE ISO, ARPA-H-SOL-26-142, Amendment 02: The purpose of ARPA-H-SOL-26-142, Amendment 02 is to revise the following sections as shown in the highlighted text: Table of Contents TA1: CVD Agent Reliable Agentic Care Management under Section 1.2.1 Technical Areas (TA) Phase 2 (15 months) Scalability Studies under Section 1.2.2 Program Structure & Timeline Section 3. Submission Information Section 4.1 Solution Summary Review Process Section 4.2 Full Proposal Evaluation Criteria Section 4.2.1 Criteria 1: Overall Scientific and Technical Merit Section 4.4 Handling of Sensitive Information See attached ADVOCATE ISO, ARPA-H-SOL-26-142, Amendment 02. __________________________ February 5, 2026 ADVOCATE ISO, ARPA-H-SOL-26-142, Amendment 01: The purpose of ARPA-H-SOL-26-142, Amendment 01 is as follows: Make a correction to Table 7 Performer Collaboration Expectations under Section 1.2.5 Performer Collaboration Expectations (See highlighted text). Revise the last paragraph under Section 5.1 Proposing Teams (See highlighted text) to read: Proposers interested in submitting a proposal for TA3 cannot submit a proposal for TA1 and TA2 in any capacity (e.g. prime, subperformer, or multi-party team). TA3 proposers can only submit one proposal for the TA3 work outlined in this solicitation. Update the first sentence of Section 6.2 Organization Conflicts of Interest (OCI) (See highlighted text) to read: The proposer, through submission of a proposal, is required to identify and disclose all facts relevant to any potential OCI involving the proposer, its organization, and/or any proposed team member (i.e. proposed sub-performer, consultant). See attached ADVOCATE ISO, ARPA-H-SOL-26-142, Amendment 01. ___________________ January 13, 2026 The Advanced Research Projects Agency for Health (ARPA-H) Agentic AI-Enabled Cardiovascular Care Transformation (ADVOCATE) program will enable the development of an Agentic system that delivers autonomous and semi-autonomous clinical care directly to patients with cardiovascular disease (CVD). Interested parties are invited to review the attached ADVOCATE Innovative Solutions Opening (ISO) ARPA-H -SOL-26-142. For detailed information regarding the ADVOCATE Proposers' Day, review Special Notice (SN) ARPA-H-SN-26-139.